This study aims to assess the prevalence of short birth spacing (SBS) in association with demographic and socio-economic factors in India with special reference to maternal and child health. This study ...
This study investigates barriers to the utilization of antiretroviral therapy among HIV-positive pregnant women in Birnin Kebbi, North West Nigeria. This study concludes that interventions focusing on community education to reduce ...
The objective of the study was to estimate associations between the index of concentration at the extremes (ICE) -a proxy for anti-Black structural racism- and hospital-reported perinatal mental disorders (PMD). Findings reveal ...
As I boarded the flight from Lagos to Cape Town, I had no idea the journey ahead would teach me as much as the conference I was attending. I met ...
The KEMRI-Wellcome Research Programme is a health research institute based in Kenya. Community engagement for every research project is supported by a "CAST" team. Community engagement Advice for Study Teams (CASTs) ...
CEPI hopes to identify a group of implementing partners who can help achieve its Biosecurity Strategy. CEPI is looking for partners who can support different types of activities, across diverse geographic settings, related to its biosecurity objectives Read more
CEPI has announced a funding opportunity to develop innovative analytical technologies for vaccines. The goal is to reduce vaccine development, manufacturing, and release times; lower costs, improve equitable deployment in Low to Middle-Income Countries, and enhance analytical insights for vaccines. Read more
A global consortium led by Danish biotech AdaptVac is developing a vaccine that combines AI-designed immunogens, components that trigger immune response, with AdaptVac’s virus-like particle platform, which mimics real viruses to safely stimulate immunity against multiple deadly filoviruses. Read more
This article delves into the challenges and potential solutions, complemented by several case studies, concerning the establishment of robust and resilient vaccine manufacturing and supply chains in low- and middle-income countries Read more
SPEAC announces the release of a comprehensive Companion Guide for the Brighton Collaboration Case Definition of Single Organ Cutaneous Vasculitis (SOCV). This new resource combines a wealth of tools and guidance to standardize vaccine safety assessments and pharmacovigilance efforts worldwide. Read more
The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more
Resources
In collaboration with TGHN, CEPI created this playbook to bring together the many tools, resources and materials generated for pandemic preparedness and response from the COVID-19 pandemic. The first (Regulatory) chapter is now available.
TRANSVAC Academy offers training modules in vaccine R&D including grant management, statistics, cytometry and advanced process development. CEPI funded scholarships are provided to selected applicants from LMICs.
SPEAC is a CEPI and Brighton Collaboration project. SPEAC provides vaccine safety tools, resources, and expertise throughout the vaccine development process to enhance safety and build confidence in vaccines.
Monitoring Vaccine Performance against SARS CoV-2 Variants
The IVAC COVID-19 Vaccine Effectiveness Project (a CEPI- funded global systematic review which also includes neutralization capacity) outputs are publicly available on VIEWhub to assist all policy makers
International Pandemic Preparedness Secretariat
The IPPS serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission, across vaccines, therapeutics, and diagnostics. It performs a global annual progress review related to the 100 DM which feeds into implementation reports.
Vaccine Development
Process Maps
The UK Vaccine R&D Network has developed vaccine development maps to show key stages in human and veterinary vaccines development up to Phase III clinical trials. These process maps and associated case studies provide support in understanding key stages in vaccine development and where bottlenecks could cause delays.
